Blog

The FDA is aware of two new studies that shows an increased risk of blood clots in patients taking prescriptions containing drospirenone, including Yaz and Yasmin.

A recent US Food and Drug Administration (FDA) MedWatch release confirmed that the FDA is aware of two new studies that shows an increased risk of venous thromboembolism (VTE), or blood clots, in patients taking prescriptions containing drospirenone. Drospirenone is a progestin, and is used in many popular birth control medications including Yaz (generics include Gianvi and Loryna), Yasmin (generics include Ocella, Syeda, and Zarah), Beyaz, and Safyral.

When compared to birth control medications that contain a different progestin, drospirenone can increase the risk of a blood clot by two to three times. The FDA is currently recommending that women who develop any symptom of a blood clot (including persistent leg pain, severe chest pain, or sudden shortness of breath) should contact their doctor immediately. It is currently not recommended to immediately stop drospirenone medications without first consulting your doctor.

If you or a loved one has experienced a venous thromboembolism while taking Yaz, Yasmin, or any other birth control containing drospirenone, contact The Law Offices of Larry H. Parker today at (800) 333-0000 for a free consultation. You may be entitled to compensation.